title: Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study.
authors.forename: Greg
authors.initials: G
authors.lastname: Flaker
authors.forename: Michael
authors.initials: M
authors.lastname: Ezekowitz
authors.forename: Salim
authors.initials: S
authors.lastname: Yusuf
authors.forename: Lars
authors.initials: L
authors.lastname: Wallentin
authors.forename: Herbert
authors.initials: H
authors.lastname: Noack
authors.forename: Martina
authors.initials: M
authors.lastname: Brueckmann
authors.forename: Paul
authors.initials: P
authors.lastname: Reilly
authors.forename: Stefan H
authors.initials: SH
authors.lastname: Hohnloser
authors.forename: Stuart
authors.initials: S
authors.lastname: Connolly
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D001562:Benzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D000069604:Dabigatran; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography; D004617:Embolism / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D005500:Follow-Up Studies; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D016032:Randomized Controlled Trials as Topic; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*; D013614:Tachycardia, Paroxysmal / Q000188:drug therapy* / Q000503:physiopathology; D013997:Time Factors; D016896:Treatment Outcome; D014859:Warfarin / Q000008:administration & dosage / Q000627:therapeutic use*; D015091:beta-Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D015091:beta-Alanine; D014859:Warfarin; D000069604:Dabigatran